Claims for Patent: 9,211,341

Summary for Patent: 9,211,341

Title:	Method of manufacturing a pharmaceutical composition having chelating type complex micelles
Abstract:	This invention provides Chelating Complex Micelles as a drug carrier. The Chelating Complex Micelles can load drugs without changing their structure, and therefore extend the half-life of drugs in the human body. The chelating complex micelles contain a metal ion core, at least one polymer, and at least one drug molecule. The metal ion is considered as a Lewis acid while polymer chain and drug molecules are referred to as Lewis bases. The drug molecule is linked to the polymer via forming coordinate bonds with metal ion, and then self-assembled to form chelating complex micelles as a drug carrier.
Inventor(s):	Wang; Chau-Hui (Kaohsiung, TW), Chen; Chia-Hung (New Taipei, TW), Lin; Johnson (Taipei, TW), Chen; Jing-Yi (Taipei, TW), Liao; Wei-Chuan (Kaohsiung, TW)
Assignee:	ORIGINAL BIOMEDICALS CO., LTD. (Tainan City, TW)
Application Number:	14/306,775
Patent Claims:	1. A method of manufacturing a pharmaceutical composition having chelating type complex micelles, comprising: providing a raw material, said raw material contains a Lewis base drug, a Lewis base ligand and a ligand-free Lewis acid metal ion core; and placing said raw materials in a buffer solution followed by continuous mixing, whereby said Lewis base drug, said Lewis base ligand, and said Lewis acid metal ion core are self-assembled to form the chelating complex micelles, wherein said Lewis base drug and said Lewis base ligand are linked together due to the forming of coordinate bonds with said Lewis acid metal ion core at the same time wherein the Lewis base ligand is poly(ethylene glycol)-b-poly(glutamic acid) (PEG-b-PGA). 2. The method of manufacturing a pharmaceutical composition having chelating complex micelles of claim 1, wherein said Lewis acid metal ion core is one or more selected from the group consisted of: Fe, Cu, Ni, In, Ca, Co, Cr, Gd, Al, Sn, Zn, W, Sc, Ti, Mn, V, Mg, Be, La, Au, Ag, Cd, Hg, Pd, Re, Tc, Cs, Ra, Ir and Ga. 3. The method of manufacturing a pharmaceutical composition having chelating complex micelles of claim 1, wherein said Lewis base drug contains one or more functional groups, which are selected from the following groups of carboxylic acids, alcohols, ketones, furans, amines, anilines, pyrroles, thiols, esters, amides, imines, pyridines, pyrimidines, imidazoles, pyrazols, sulfonamides, phosphonic acids, and any combination thereof. 4. The method of manufacturing a pharmaceutical composition having chelating complex micelles of claim 1, wherein said Lewis base drug is selected from a group of amifostine, WR-1065, doxorubicin, pemetrexed, gemcitabine, methotrexate, docetaxel, vinblastine, epirubicin, topotecan, irinotecan, ifosfamide, gefitinib, erlotinib, penicillin class, cloxacillin, dicloxacillin, gentamicin, vancomycin, amphotericin, quinolones, piperazine, fluoroquinolone, nalidixic acid, ciprofloxacin, levofloxacin, trovafloxacin, oseltamivir, metformin, trastuzumab, imatinib, rituximab, bevacizumab, celecoxib, etodolac, ibuprofen, cyclosporine, morphine, erythropoietin, granulocyte colony-stimulating factor, curcumin (enol, keto form), glutathione, Vitamin C, acetylcysteine, carnitine, galantamine, insulin, imipenem, cilastatin, ertapenem, meropenem, entecavir, telbivudine, lamivudine, melatonin, tocopherols, tocotrienol (Vitamin E), L-carnitine, carotenes, ubiquinol, lipoic acid, polyphenols, catecholamine, resveratrol, piceid, tempo, asarone, aminoguanidine, tocopherol monoglucoside, glycyrrhizic acid, epicatechin, flavonoid, orientin, vicenin, MPG (2-mercaptopropionyl glycine), Mesna (2-mercaptoethanesulfonic acid), and any combination thereof. 5. The method of manufacturing a pharmaceutical composition having chelating complex micelles of claim 1, wherein the buffer solution comprises a HEPES [4-(2-hydroxyethyl) 1-piperazine-ethanesulfonic acid)]. 6. The method of manufacturing a pharmaceutical composition having chelating complex micelles of claim 1, wherein the buffer solution has a pH of 6.5 to 7.5. 7. The method of manufacturing a pharmaceutical composition having chelating complex micelles of claim 1, wherein the mixing is performed at a temperature between 4 to 40.degree. C. 8. A method of manufacturing a pharmaceutical composition having chelating type complex micelles, comprising: providing a raw material, the raw material contains an amifostine, a PEG-b-PGA and FeCl.sub.2; and placing the raw material in a buffer solution followed by continuous mixing, whereby the amifostine, the PEG-b-PGA, and the ferrous ion Fe.sup.2+ are self-assembled to form the chelating complex micelles wherein the amifostine and the PEG-b-PGA are linked together due to the forming of coordinate bonds with the ferrous ion Fe.sup.2+ at the same time. 9. The method of manufacturing a pharmaceutical composition having chelating complex micelles of claim 8, wherein the amifostine weights between 0.1-10 mg, the PEG-b-PGA weights between 0.1-100 mg, and the FeCl.sub.2 weights between 0.01 to 50 mg. 10. The method of manufacturing a pharmaceutical composition having chelating complex micelles of claim 8, wherein the amifostine's concentration is about 0.01-10 mg/mL. 11. The method of manufacturing a pharmaceutical composition having chelating complex micelles of claim 8, wherein the buffer solution is HEPES [4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid)]. 12. The method of manufacturing a pharmaceutical composition having chelating complex micelles of claim 8, wherein the buffer solution has a pH of 6.5 to 7.5. 13. The method of manufacturing a pharmaceutical composition having chelating complex micelles of claim 8, wherein the mixing is performed at a temperature between 4 to 40.degree. C.

Details for Patent 9,211,341

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2032-11-21
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2032-11-21
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2032-11-21
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2032-11-21
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2032-11-21
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2032-11-21